Clinical Trial Update: Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating how itraconazole affects the pharmacokinetics of AZD9291 (osimertinib) in patients with EGFR-positive non-small cell lung cancer; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Itraconazole (Itraconazole)
• Osimertinib (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2016-04-14